Novel inhibitors of Rac1 in metastatic breast cancer

Puerto Rico Health Sciences Journal

Volumn 29, Issue 4, 2010, Pages 348-356

  Hernández, Eliud ^a   de la Mota Peynado, Alina ^b   Dharmawardhane, Surangani ^b   Vlaar, Cornelis P ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

Author keywords

Breast cancer; GTPase; Inhibitor; Metastasis; Rac1

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AMINOQUINOLINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAC1 PROTEIN;

ARTICLE; BREAST TUMOR; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; METASTASIS; PATHOLOGY; TUMOR CELL CULTURE;

AMINOQUINOLINES; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASM METASTASIS; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; TUMOR CELLS, CULTURED;

EID: 78649397040     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Jemal A, Sigel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics 2009. CA Cancer J Clin 2009:225-249.
2. Jones SE. Metastatic breast cancer: the treatment challenge. Clin. Breast Cancer 2008;8:224-233.
3. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 2006;16:522-529.
4. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005;33:891-895.
5. Lin M, van Golen KL. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 2004;84:49-60.
6. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD. RhoC-GTPase is a novel tissue biomark-er associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93:101-110.
7. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR, Symons M. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005;24:7821-7829.
8. Sawyer TK. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 2004;13:1-19.
9. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta (BBA) - Reviews on Cancer 2009;1796(2):91-98.
10. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through RhoGTPase pathway as viable drug target. Curr Med Chem 2009;16(11):1355-1365.
11. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through RhoGTPase pathway as viable drug target. Curr Med Chem 2009;16(11):1355-1365.
12. Surviladze Z, Waller A, Wu Y, Romero E, Edwards BS, Wandinger-Ness A, Sklar L. Identification of a Small GTPase Inhibitor Using a High-Throughput Flow Cytometry Bead-Based Multiplex Assay. J Biomol Screen 2010;15:10-20.
13. Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 2002;420:629-635.
14. Jaffe AB, Hall A: Rho GTPases: biochemistry and biology. Ann Rev Cell Dev Biol 2005;21:247-269.
15. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GT-Pases: turning on the switch. Genes Dev 2002;16:1587-1609.
16. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003:1603:47-82.
17. Palmby TR, Abe K, Karnoub AE, Der CJ. Vav transformation requires activation of multiple GTPases and regulation of gene expression. Mol Cancer Res 2004;2:702-711.
18. Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CM. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol 2005;19:939-949.
19. Sastry SK, Rajfur Z, Liu BP, Cote JF, Tremblay ML, Burridge K. PTP-PEST couples membrane protrusion and tail retraction via VAV2 and p190RhoGAP. J Biol Chem 2006;281:11627-11636.
20. Bouquier N, Vignal E, Charrasse S, Weill M, Schmidt S, Léonetti J-P, Blangy A, Fort P. A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signalling pathway. Chem Biol 2009;16(6): 657-666.
21. Minard ME, Kim LS, Price JE, Gallick GE. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 2004;82:21-32.
22. Strumane K, Rygiel T, van der Valk M, Collard JG. Tiam-1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc. J Cancer Res Clin Oncol 2009;135(1):69-80.
23. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682-687.
24. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y, Yoshida K-I. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004;10:4799-4805.
25. Liu S-Y, Yen C-Y, Yang S-C, Chiang W-F, Chang K-W. Overexpression of Rac-1 small GTPase binding protein in oral squamous cell carcinoma. Journal of Oral and Maxillofacial Surgery 2004;62(6):702-707.
26. Gómez del Pulgar T, Bandrés E, Espina C, Valdés-Mora F, Pérez-Palacios R, García-Amigot F, García-Foncillas J, Lacal JC. Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. Int J Biochem Cell Biol 2007;39(12):2289-2302.
27. Engers R, Ziegle S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 2007;14(2):245-256.
28. Espina C, Céspedes MV, García-Cabezas MA, Gómez del Pulgar MT, Boluda A, García Oroz L, Cejas P, Nistal M, Mangues R, Lacal JC. A critical role for Rac1 in tumor progression of human colorectal adeno-carcinoma cells. Am J Pathol 2008;172(1):156-166.
29. Wang J, Rao Q, Wang M, Wei H, Xing H, Liu H, Wang Y, Tang K, Peng L, Tian Z, Wang J. Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth. Biochem Biophys Res Commun 2009;386(4): 769-774.
30. Adam L, Vadlamudi RK, McCrea P, Kumar R. Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 2001;276:28443-28450.
31. Liu L, Wu DH, Ding YQ. Tiam1 gene expression and its significance in colorectal carcinoma. World J Gastroenterol 2005;11:705-707.
32. Minard ME, Ellis LM, Gal-lick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis 2006;23:301-313.
33. Lane J, Martin TA, Mansel RE, Jiang WG. The expression and prognostic value of guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int Seminars in Surgical Oncol 2008;5:23.
34. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD. RhoC GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005;93:101-110.
35. Burbelo P,Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 2004;84:43-48.
36. Azios NG, Krishnamoorthy L, Harris M, Cubano LA, Cammer M, Dharmawardhane SF. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia 2007;9:147-158.
37. Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res. 2005;7:R965-R974.
38. Worthylake DK, Rossman KL, Sondek J. Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1. Nature 2000; 408(6813):682-688.
39. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. PNAS 2004;101:7618-7623.
40. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y, Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol 2006;406:554-565.
41. Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007; 12:467-478.
42. Binker MG, Binker-Cosen AA, Gaisano HY, and Cosen-Binker LI. Inhibition of Rac1 decrease the severity of pancreatitis and pancreatitis-associated lung injury in mice. Exp Physiol 2008; 93:1091-1103.
43. Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009;8: 1557-1569.
44. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009;69(13):5292-3.
45. Gao Y, Xing J, Streuli M, Leto TL, Zheng Y, Trp(56) of Rac1 specifies interaction with a subset of guanine nucleotide exchange factors. J Biol Chem 2001; 276:47530-47541.
46. Dokmanovic M., Hirsch, DS, Shen Y, Wu Wu J. Rac1 contributes to tras-tuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther. 2009 Jun;8(6):1557-69.
47. Zheng Y, Nassar N, Skowronek KR. GTPase inhibitors and methods of use and crystal structure of RAC-1 GTPase. 2007;US Patent Application #20070155766.
48. Ferri N, Corsini A, Bottino P, Clerici F, Contini A. Virtual Screening Approach for the Identification of New Rac1 Inhibitors. J Med Chem 2009; 52(14):4087-4090.
49. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 1998;19:1639-1662.
50. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempiri-cal free energy force field with charge-based desolvation. J Comp Chem 2007;28: 1145-1152.